Smallpox Pipeline Summary

DelveInsight’s, “Smallpox - Pipeline Insight, 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Smallpox pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Smallpox: Understanding

Smallpox: Overview

Smallpox is a highly contagious viral disease caused by the variola virus, a member of the Orthopoxvirus genus within the Poxviridae family. It was the first human infectious disease to be successfully eradicated worldwide, with the World Health Assembly certifying eradication in 1980 following an extensive global vaccination campaign. Although naturally occurring smallpox no longer exists, it remains a public health concern because of the potential risk of accidental or deliberate release as a bioterrorism agent. The disease is characterized by an initial febrile prodrome followed by the development of a distinctive centrifugal vesiculopustular rash.

Smallpox is caused exclusively by the variola virus, a large, brick-shaped, double-stranded DNA virus that infects only humans, with no known animal reservoir. Transmission occurs primarily through respiratory droplets during prolonged face-to-face contact, although direct contact with infected skin lesions or contaminated fomites can also spread the virus. Infected individuals become contagious once lesions develop in the oropharynx and remain infectious until all skin crusts have separated.

Following inhalation, the variola virus enters through the oropharyngeal or nasopharyngeal mucosa and replicates within regional lymph nodes. An initial viremia develops approximately 3–4 days after infection, allowing dissemination to the spleen, bone marrow, and additional lymphatic tissues. A secondary viremia occurs around days 8–12, coinciding with the onset of fever and systemic symptoms. The virus subsequently localizes within the dermal blood vessels and oropharyngeal mucosa, resulting in the characteristic synchronous progression of skin lesions from macules to papules, vesicles, pustules, and finally crusts.

Diagnosis of suspected smallpox relies on clinical assessment supported by public health guidelines. Key diagnostic features include a febrile prodrome, deep-seated lesions with a classic appearance, and lesions that are all at the same stage of development. Additional findings such as centrifugal rash distribution, involvement of the palms and soles, lesions initially appearing in the oral cavity or on the face and forearms, and slow lesion progression further increase suspicion. In individuals classified as high risk, laboratory confirmation is performed using polymerase chain reaction (PCR) testing on blood or lesion specimens following consultation with public health authorities.

Historically, treatment for smallpox consisted primarily of supportive care, including hydration, nutritional support, fever management, and treatment of secondary bacterial infections. Since eradication, antiviral therapies targeting orthopoxviruses have been developed, with tecovirimat becoming the first antiviral approved in the United States for the treatment of smallpox in 2018. Although its efficacy against naturally occurring smallpox cannot be evaluated because the disease has been eradicated, evidence from animal studies and human safety trials supports its use in preparedness efforts. Vaccination remains the cornerstone of prevention, with current recommendations limited to individuals at occupational risk of exposure, such as laboratory personnel and selected healthcare or military personnel.

"Smallpox- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Smallpox pipeline landscape is provided which includes the disease overview and Smallpox treatment guidelines. The assessment part of the report embraces, in depth Smallpox commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Smallpox collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Smallpox R&D. The therapies under development are focused on novel approaches to treat/improve Smallpox.

Smallpox Emerging Drugs Chapters

This segment of the Smallpox report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Smallpox Emerging Drugs

• TNX-801: Tonix Pharmaceuticals

TNX-801 is an investigational, single-dose, attenuated, minimally replicative live recombinant horsepox virus vaccine which is based on synthesized horsepox virus and is administered percutaneously. TNX-801 acts by eliciting immune responses against orthopoxviruses to provide protection against subsequent viral exposure. Though it shares structural characteristics with vaccinia-based vaccines, TNX-801 has unique properties that the company believes it may lower toxicity and offer potential safety advantages over existing vaccinia-based vaccines, which have been associated with adverse side effects such as myocarditis/pericarditis. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Smallpox.

Further product details are provided in the report……..

Smallpox: Therapeutic Assessment

This segment of the report provides insights about the different Smallpox drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Smallpox

There are approx. 4+ key companies which are developing the therapies Smallpox. The companies which have their Smallpox drug candidates in the most advanced stage, i.e. Preclinical stage include, Tonix Pharmaceuticals and others.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Smallpox pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Smallpox: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Smallpox therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Smallpox drugs.

Smallpox Report Insights

• Smallpox Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Smallpox Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Smallpox drugs?
• How many Smallpox drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Smallpox?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Smallpox therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Smallpox and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tonix Pharmaceuticals
• BioNtech SE

Key Products

• TNX-801
• BNT166a